# Phase I/IIa Study of FIXFc in Hemophilia B Patients

> **NCT00716716** · PHASE1 · COMPLETED · sponsor: **Bioverativ Therapeutics Inc.** · enrollment: 10 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** rFIXFc

## Key facts

- **NCT ID:** NCT00716716
- **Lead sponsor:** Bioverativ Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716716, "Phase I/IIa Study of FIXFc in Hemophilia B Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00716716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*